Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3	NOV 26	MARPAT enhanced with FSORT command
NEWS 4	NOV 26	CHEMSAFE now available on STN Easy
NEWS 5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6	DEC 01	ChemPort single article sales feature unavailable
NEWS 7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14	FEB 10	COMPENDEX reloaded and enhanced
NEWS 15	FEB 11	WTEXTILES reloaded and enhanced
NEWS 16	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26	MAR 20	CAS databases on STN enhanced with new super role

```
                for nanomaterial substances
 NEWS 27  MAR 23  CA/CAplus enhanced with more than 250,000 patent
                  equivalents from China
 NEWS 28  MAR 30  IMSPATENTS reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:28:31 ON 30 MAR 2009

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 11:28:43 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAR 2009  HIGHEST RN 1128305-29-2
DICTIONARY FILE UPDATES:  27 MAR 2009  HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10553982 updated.str
```

chain nodes :
6 7 11 12
ring nodes :
1 2 3 4 5 9
chain bonds :
1-6 3-12 4-11 6-7 6-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-12 4-5 4-11 6-7 6-9
exact bonds :
1-6
isolated ring systems :
containing 1 :

G1:O,S

G2:Cb,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 9:Atom 11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S
G2 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 11:29:02 ON 30 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14
FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

```
FULL SEARCH INITIATED 11:29:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   234495 TO ITERATE

 81.3% PROCESSED   190655 ITERATIONS                                462 ANSWERS

100.0% PROCESSED   234495 ITERATIONS                                462 ANSWERS
SEARCH TIME: 00.00.21

L2          462 SEA SSS FUL L1


L3            9 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2006:380879  CAPLUS  Full-text
DOCUMENT NUMBER:          144:432814
TITLE:                    Preparation of 1,5-diheterocyclyl-1H-triazole
                          derivatives as platelet aggregation inhibitors
INVENTOR(S):              Kanaya, Naoaki; Fujii, Kunihiko
PATENT ASSIGNEE(S):       Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 123 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------            ----   --------    -------------------      --------
     WO 2006043594          A1    20060427    WO 2005-JP19207          20051019
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
             NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
             SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2005296582          A1    20060427    AU 2005-296582           20051019
     CA 2583153             A1    20060427    CA 2005-2583153          20051019
     EP 1803719             A1    20070704    EP 2005-795875           20051019
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 101039934           A     20070919    CN 2005-80035228         20051019
     NO 2007001826          A     20070614    NO 2007-1826             20070410
     KR 2007063530          A     20070619    KR 2007-708162           20070410
     MX 2007004643          A     20070608    MX 2007-4643             20070418
     US 20080125409         A1    20080529    US 2007-577476           20070418
```

PRIORITY APPLN. INFO.: JP 2004-303851 A 20041019
WO 2005-JP19207 W 20051019

OTHER SOURCE(S): MARPAT 144:432814

GI



I

AB The title compds. represented by the general formula (I) [wherein Ar1, Ar2 = (un)substituted 5- or 6-membered aromatic heterocyclyl; R1, R2 = H, each (un)substituted lower alkyl, alicyclic heterocyclyl, carbamoyl, or NH2 HO; or NR1R2 together represents an (un)substituted 4- to 7-membered alicyclic heterocyclyl optionally containing one N or O atom other than the ring N atom], salts thereof, or solvates of either are prepared These compds. are potent platelet aggregation inhibitors which inhibit neither COX-1 nor COX-2, and are useful for the prevention and treatment of ischemic diseases. Thus, 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4- triazole-3-carboxylic acid was condensed with neopentylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, Et3N, and 1-hydroxybenzotriazole in DMF at room temperature for 48 h to give 1-(6-methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazole-3- carboxylic acid N-neopentylamide (II). II showed IC50 of 0.013 μM for inhibiting the collagen-induced aggregation of human blood platelet.

IT 787563-08-0P, 1-[[5-(5-Cyano-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-95-6P, 1-[[5-(5-Fluoro-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)

RN 787563-08-0 CAPLUS

CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884596-95-6 CAPLUS

CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-

triazol-3-yl](4-methoxy-1-piperidinyl)- (CA INDEX NAME)



IT 884597-10-8P, 1-[[5-(5-Aminomethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)

RN 884597-10-8 CAPLUS

CN Methanone, [5-[5-(aminomethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



IT 884596-93-4P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-94-5P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-96-7P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884596-97-8P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methoxypiperidine 884596-98-9P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-3,3-difluoroazetidine 884596-99-0P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methylpiperazine 884597-02-3P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(1-methyl-1H-imidazol-4-yl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884597-06-7P, 1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4-methyl-3-oxopiperazine 884597-07-8P, (2S)-1-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-2-fluoromethylpyrrolidine 884597-08-9P,

4-[[1-(6-Methoxy-3-pyridyl)-5-(5-methyl-2-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]morpholine 884597-69-5P,
1-[[5-(5-Carbamoyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine 884597-11-9P,
1-[[5-(5-Hydroxymethyl-2-pyridyl)-1-(6-methoxy-3-pyridyl)-1H-1,2,4-triazol-3-yl]carbonyl]-4,4-difluoropiperidine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,5-diheterocyclyl-1H-triazole derivs. as platelet aggregation inhibitors for prevention or treatment of ischemic diseases)

RN 884596-93-4 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884596-94-5 CAPLUS
CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyrazinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884596-96-7 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884596-97-8 CAPLUS
CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884596-98-9 CAPLUS
CN Methanone, (3,3-difluoro-1-azetidinyl)[1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884596-99-0 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 884597-02-8 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(1-methyl-1H-imidazol-4-yl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 884597-06-2 CAPLUS
CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 884597-07-3 CAPLUS
CN Methanone, [(2S)-2-(fluoromethyl)-1-pyrrolidinyl][1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 884597-08-4 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 884597-09-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 884597-11-9 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[5-[5-(hydroxymethyl)-2-pyridinyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:497497 CAPLUS Full-text
DOCUMENT NUMBER: 143:43882
TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamide derivatives showing CB1-antagonistic activity and combination treatment involving the compounds
INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Gunter; Lange, Josephus Hubertus Maria; Kruse, Cornelis Gerrit
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 27 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050124660	A1	20050609	US 2004-969840		20041022
PRIORITY APPLN. INFO.:			US 2003-513995P	P	20031027

OTHER SOURCE(S): CASREACT 143:43882; MARPAT 143:43882
GI



I

AB The present invention relates to a novel medical use of compds. with CB1-receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivs., 1H-imidazole derivs., thiazole derivs. and/or 1H-1,2,4-triazole-3-carboxamide derivs. or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compds. with

CB1-receptor activity in combination with lipase inhibitors. Said compds. are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin. I was prepared and other similar compds. were tested for human cannabinoid CB1 receptor affinity and in vitro antagonism.

IT 676457-12-8P 676457-31-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-1,2,4-triazole-3-carboxamide derivs. showing CB1-antagonistic activity)

RN 676457-12-8 CAPLUS
CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS
CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:395074 CAPLUS Full-text
DOCUMENT NUMBER: 142:447220
TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands
INVENTOR(S): Antel, Jochen; Gregory, Peter-Colin; Waldeck, Harald; Krause, Guenter; Lange, Josephus Hubertus Maria; Kruse, Chris
PATENT ASSIGNEE(S): Solvay Pharmaceuticals G.m.b.H., Germany
SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039550	A2	20050506	WO 2004-EP52639	20041022
WO 2005039550	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283056	A1	20050506	AU 2004-283056	20041022
CA 2543338	A1	20050506	CA 2004-2543338	20041022
BR 2004015851	A	20070102	BR 2004-15851	20041022
EP 1753413	A2	20070221	EP 2004-817279	20041022
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
JP 2007513872	T	20070531	JP 2006-536096	20041022
CN 1997364	A	20070711	CN 2004-80030116	20041022
MX 2006004434	A	20060620	MX 2006-4434	20060421

PRIORITY APPLN. INFO.: EP 2003-103961 A 20031024
EP 2003-103967 A 20031027
WO 2004-EP52639 W 20041022

OTHER SOURCE(S): MARPAT 142:447220
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The novel use of nitrogen heterocycles I-V [R, R1, R5, R11 = Ph, naphthyl, thienyl, pyridyl, etc.; R2, = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl; R7 = (un)branched alkyl] for treatment of cannabinoid-CB1 receptor related diseases, especially in juveniles, is described. A 4-step synthesis of triazolecarboxamide VI.HCl starting from di-Me aminomalonate.HCl 4-chlorobenzoyl chloride, 2,4-dichloroaniline, and 1-aminopiperidine is given. Furthermore, the invention pertains to the use of I-V in combination with lipase inhibitors. Preferred lipase inhibitors are olistat, panclicins, ATL-962, and/or lipstatin.

IT 676457-12-8P 676457-31-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazolecarboxamides as cannabinoid-CB1 receptor ligands for treatment of drug-induced obesity in juveniles and adolescents)

RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS
CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:927195 CAPLUS Full-text
DOCUMENT NUMBER: 141:395556
TITLE: Preparation of azole compounds as platelet aggregation inhibitors
INVENTOR(S): Okayama, Toru; Uoto, Kouichi; Ishiyama, Takashi; Kanaya, Naoaki; Kimura, Youichi; Ishihara, Hiroaki; Watanabe, Toshiyuki; Fujii, Kunihiko
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co. Ltd., Japan
SOURCE: PCT Int. Appl., 223 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094407	A1	20041104	WO 2004-JP5605	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2004232577	A1	20041104	AU 2004-232577	20040420
CA	2522536	A1	20041104	CA 2004-2522536	20040420
EP	1621537	A1	20060201	EP 2004-728462	20040420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN	1774435	A	20060517	CN 2004-80010326	20040420
NO	2005004854	A	20051115	NO 2005-4854	20051020
MX	2005011276	A	20060124	MX 2005-11276	20051020
US	20060189591	A1	20060824	US 2005-553982	20051020

PRIORITY APPLN. INFO.:
JP 2003-115204 A 20030421
JP 2004-42859 A 20040219
WO 2004-JP5605 W 20040420

OTHER SOURCE(S): MARPAT 141:395556

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. Q-X-Y (I) [Q = II, etc.; Ar1, Ar2 = (un)substituted 6-membered aromatic heterocycles; (un)substituted phenyl; R2 = H, halo, etc.; X = carbonyl, thiocarbonyl; Y = III; A = 4-7 membered ring, further detail on said ring is given; R1 = OH, etc.] were prepared For example, EDCI-mediated coupling of 2-(6-methoxy-3-pyridyl)-1-(2-pyridyl)-1H- imidazole-4-carboxylic acid with (3R)-fluoropiperidine hydrochloride afforded compound IV in 44% yield. In platelet aggregation inhibition assays, the IC50 value of compound IV was 0.11 μM. Of note, compds. I inhibit neither COX-1 nor COX-2. Disclosed compds. I are claimed useful for the treatment of ischemia.

IT 787564-53-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of azole compds. as platelet aggregation inhibitors for treatment of ischemia)

RN 787564-53-8 CAPLUS

CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



IT 787562-73-6P 787562-74-7P 787562-75-8P
787562-76-9P 787562-77-0P 787562-78-1P
787562-80-5P 787562-81-6P 787562-82-7P
787562-83-8P 787562-84-9P 787562-85-0P
787562-86-1P 787562-87-2P 787562-88-3P
787562-89-4P 787562-90-7P 787562-92-9P
787563-02-4P 787563-03-5P 787563-07-9P
787563-08-0P 787563-12-6P 787563-14-8P
787563-15-9P 787563-16-0P 787563-17-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole compds. as platelet aggregation inhibitors for treatment of ischemia)

RN 787562-73-6 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-74-7 CAPLUS
CN Methanone, [5-(4-fluorophenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-75-8 CAPLUS
CN Methanone, (4-cyclopropyl-1-piperazinyl)[1-(6-methoxy-3-pyridinyl)-5-phenyl-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-76-9 CAPLUS
CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-phenyl-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-77-0 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-78-1 CAPLUS
CN Methanone, [5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 787562-80-5 CAPLUS
CN Methanone, [3-(dimethylamino)-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-81-6 CAPLUS
CN Methanone, [5-(3-fluoro-4-methylphenyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787562-82-7 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 787562-83-8 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 787562-84-9 CAPLUS
CN Methanone, 4,7-diazaspiro[2.5]oct-7-yl[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 787562-85-0 CAPLUS

CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl](4-methyl-4,7-diazaspiro[2.5]oct-7-yl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 787562-86-1 CAPLUS
CN 2-Piperazinone, 4-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787562-87-2 CAPLUS
CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-88-3 CAPLUS
CN 2-Azetidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-N,N-dimethyl- (CA INDEX NAME)



RN 787562-89-4 CAPLUS
CN Methanone, [2-[(dimethylamino)methyl]-1-azetidinyl][1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 787562-90-7 CAPLUS
CN Methanone, [3-(dimethylamino)-2,2-dimethyl-1-azetidinyl][1-(4-methoxyphenyl)-5-(6-methyl-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787562-92-9 CAPLUS
CN 2-Piperazinone, 4-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-1-methyl- (CA INDEX NAME)



RN 787563-02-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[5-(6-methoxy-3-pyridinyl)-1-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 787563-03-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, 1-[[1-(6-methoxy-3-pyridinyl)-5-(4-methylphenyl)-1H-1,2,4-triazol-3-yl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 787563-07-9 CAPLUS
CN Methanone, [1-(6-methoxy-3-pyridinyl)-5-(2-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787563-08-0 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[3-[(4,4-difluoro-1-piperidinyl)carbonyl]-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-5-yl]- (CA INDEX NAME)



RN 787563-12-6 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-14-8 CAPLUS
CN Methanone, [5-(5-fluoro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 787563-15-9 CAPLUS
CN Methanone, (4,4-difluoro-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-16-0 CAPLUS
CN Methanone, (4-methoxy-1-piperidinyl)[1-(6-methoxy-3-pyridinyl)-5-(5-methyl-2-pyridinyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



RN 787563-17-1 CAPLUS
CN Methanone, [5-(5-chloro-2-pyridinyl)-1-(6-methoxy-3-pyridinyl)-1H-1,2,4-triazol-3-yl](4,4-difluoro-1-piperidinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:589415 CAPLUS Full-text
DOCUMENT NUMBER: 141:140441
TITLE: Preparation of imidazole and triazole derivatives useful as selective COX-1 inhibitors
INVENTOR(S): Takahashi, Fumie; Nakagawa, Toshiya; Matsushima, Yuji; Nakamura, Katsuya
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060367	A1	20040722	WO 2003-JP15921	20031212

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003288746 A1 20040729 AU 2003-288746 20031212

PRIORITY APPLN. INFO.: AU 2002-953602 A 20021230
AU 2003-901804 A 20030415
AU 2003-903928 A 20030728
WO 2003-JP15921 W 20031212

OTHER SOURCE(S): MARPAT 141:140441

GI



I

AB Imidazole and triazole derivs. were prepared for use as selective COX-1 inhibitors for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodegenerative diseases. Thus, 4-PhCH2OCH2CH2C6H4NH2 was treated with 4-MeOC6H4CN to give 4-PhCH2OCH2CH2C6H4NHC(:NH)C6H4OMe-4 which was cyclized with BrCH2COCF3 and debenzylated to give the imidazole I. I had IC50 for COX-1 inhibition of < 0.01 and an analgesic coefficient relative to controls of > 1.5.

IT 726197-06-4P 726197-20-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)

RN 726197-06-4 CAPLUS

CN Methanone, [5-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 726197-20-2 CAPLUS

CN Methanone, [1-(4-methoxyphenyl)-5-[4-(phenylmethoxy)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



IT 726195-26-2P 726195-46-6P 726195-54-6P
726195-64-8P 726195-74-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole and triazole derivs. useful as selective COX-1 inhibitors)

RN 726195-26-2 CAPLUS
CN Methanone, [5-[4-(2-hydroxyethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 726195-46-6 CAPLUS
CN Carbamic acid, [2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 726195-54-6 CAPLUS
CN Urea, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 726195-64-8 CAPLUS
CN Methanesulfonamide, N-[2-[4-[1-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)-1H-1,2,4-triazol-5-yl]phenoxy]ethyl]- (CA INDEX NAME)



RN 726195-74-0 CAPLUS
CN Methanone, [5-[4-(2-aminoethoxy)phenyl]-1-(4-methoxyphenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:272442 CAPLUS Full-text

DOCUMENT NUMBER: 140:303680
TITLE: Preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands
INVENTOR(S): Lange, Josephus H. m.; Kruse, Cornelis G.; McCreary, Andrew C.; Van Stuivenberg, Herman H.
PATENT ASSIGNEE(S): Solvay Pharmaceuticals B.V., Neth.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026301	A1	20040401	WO 2003-EP50628	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1402891	A1	20040331	EP 2002-78966	20020919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20040106614	A1	20040603	US 2003-662477	20030916
US 7319110	B2	20080115		
CA 2491394	A1	20040401	CA 2003-2491394	20030917
AU 2003299024	A1	20040408	AU 2003-299024	20030917
AU 2003299024	B2	20080306		
BR 2003012020	A	20050322	BR 2003-12020	20030917
EP 1542678	A1	20050622	EP 2003-797318	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671377	A	20050921	CN 2003-817352	20030917
CN 1319529	C	20070606		
JP 2006501275	T	20060112	JP 2004-537155	20030917
RU 2325382	C2	20080527	RU 2005-103244	20030917
IN 2004CN03228	A	20060303	IN 2004-CN3228	20041213
ZA 2005000133	A	20051101	ZA 2005-133	20050106
MX 2005002862	A	20050527	MX 2005-2862	20050315
NO 2005001870	A	20050603	NO 2005-1870	20050418
HK 1078796	A1	20071012	HK 2005-110963	20051201

PRIORITY APPLN. INFO.: EP 2002-78966 A 20020919
WO 2003-EP50628 W 20030917

OTHER SOURCE(S): MARPAT 140:303680
GI

I

AB The title compds. [I; R, R1 = Ph, naphthyl, thienyl, pyridyl, etc.; R2 = H, alkyl, cycloalkylalkyl, Ph, etc.; R3 = alkyl, alkoxy, cycloalkyl, etc.; or NR2R3 = (un)saturated monocyclic or bicyclic heterocyclyl] which are potent cannabinoid-CB1 receptor agonists, partial agonists, inverse agonists or antagonists, useful for the treatment of disorders involving cannabinoid neurotransmission, were prepared E.g., a 4-step synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,4- triazole-3-carboxamide hydrochloride, starting from di-Me aminomalonate.HCl and 4-chlorobenzoyl chloride, was given. The compds. I were tested for in vitro affinity and in vitro antagonism at human cannabinoid-CB1 receptors. The biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound I is claimed.

IT 676457-12-8P 676457-31-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1H-1,2,4-triazole-3-carboxamides as cannabinoid-CB1 receptor ligands)

RN 676457-12-8 CAPLUS

CN Methanone, [5-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 676457-31-1 CAPLUS

CN Methanone, [1,4'-bipiperidin]-1'-yl[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:153570 CAPLUS Full-text
DOCUMENT NUMBER: 140:391240
TITLE: Potent imidazole and triazole CB1 receptor antagonists related to SR141716
AUTHOR(S): Dyck, Brian; Goodfellow, Val S.; Phillips, Teresa; Grey, Jonathan; Haddach, Mustapha; Rowbottom, Martin; Naeve, Gregory S.; Brown, Brock; Saunders, John
CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., San Diego, CA, 92121, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1151-1154
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:391240
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB1 receptor. Suitably substituted imidazoles are comparably potent to the clin. candidate, whereas the analogous triazoles are less so due to the absence of an addnl. substituent on the azole ring. Example compds. thus prepared and evaluated were derivs. of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H- pyrazole-3-carboxamide (SR 141716) (I), such as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(hexahydro-1H-azepin-1-yl)-1H- 1,2,4-triazole-3-carboxamide (II) and 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(hexahydrocyclopenta[c]pyrrol- 2(1H)-yl)-5-methyl-1H-imidazole-4-carboxamide (III).

IT 683208-86-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidazolecarboxamides and triazolecarboxamides related to SR 141716 and study of their activity as cannabinoid CB1 receptor antagonists)
RN 683208-86-8 CAPLUS

CN Methanone, [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1974:505370 CAPLUS Full-text
DOCUMENT NUMBER: 81:105370
ORIGINAL REFERENCE NO.: 81:16667a,16670a
TITLE: Heterocyclization of α-acylamino amides. III. Properties of 5-aminooxazoles
AUTHOR(S): Clerin, Daniel; Fleury, Jean P.
CORPORATE SOURCE: Lab. Chim. Org. Gen., Ec. Super. Chim., Mulhouse, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1974), (1-2, Pt. 2), 211-17
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
GI For diagram(s), see printed CA Issue.
AB Treatment of 5-amino-2-aryl(or alkyl)oxazoles (I; R2N = piperidino, 1-pyrrolidinyl, morpholino; R1 = Ph, p-O2NC6H4, p-MeC6H4, Me) with electrophiles gave: with H3O+, R2NCOCH2NHCOR1; with (CF3CO)2I, 4-CF3CO derivs. of I; with PhNCO and PhNCS, 4-PhNHCO and 4-PhNCS derivs. of I; with arenediazonium salts, 4-position addition products, some of which rearranged to s-triazoles; and with sulfonyl azides, R2SO2N3 (R = Me, p-MeC6H4), cycloaddn. products which rearranged with N elimination, then reacted with a second mol. of I to give II. When I had a Me group in the 4-position, reaction with arenediazonium salts opened the ring.
IT 53423-03-3P 53423-04-4P 53423-19-1P
53423-20-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 53423-03-3 CAPLUS
CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-4-morpholinyl- (CA INDEX NAME)



RN 53423-04-4 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-4-morpholinyl- (CA INDEX NAME)



RN 53423-19-1 CAPLUS
CN Methanone, [5-(4-nitrophenyl)-1-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 53423-20-4 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-(4-nitrophenyl)-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1961:131227 CAPLUS Full-text
DOCUMENT NUMBER: 55:131227
ORIGINAL REFERENCE NO.: 55:24729e-i
TITLE: Action of organomagnesium compounds, piperidine, and aromatic thiols on 4-arylazo-2-phenyloxazolin-5-ones
AUTHOR(S): Asker, Wafia; Elagroudi, Zien E.
CORPORATE SOURCE: Cairo Univ., Giza, Egypt
SOURCE: Journal of Organic Chemistry (1961), 26, 1440-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal

LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 55:131227
GI For diagram(s), see printed CA Issue.
AB The action of excess R'MgX on RNHN:C.N:CPh.O.CO (I) gave 1H-1,2,4-triazoles, RN.CPh:N.C(CR'2OH):N (II). Thus, adding 1 g. I (R = Ph) in 50 ml. C6H6 to PhMgBr (from 0.9 g. Mg and 9 g. PhBr in 50 ml. Et2O), refluxing the mixture 3 hrs., keeping it overnight at 25°, decompg, it with saturated aqueous NH4Cl, extracting with Et2O, evaporating the dried Et2O extract, and triturating the residue with petr. ether gave 60% II (R and R' = Ph), m. 180°. The appropriate I and R'MgBr gave the following II (R, R', % yield, and m.p. given): Ph, p-MeC6H4, 70, 189°, o-MeC6H4, Ph, 60, 152°; p-MeC6H4, Ph, 55, 145°; β-C10H7, Ph, 50, 201°. The products turned red with H2SO4. The action of piperidine on I caused a rearrangement to 1H-1,2,4-triazoles, RN.CPh:N.C(CONC5H10):N (III). Thus, adding 0.5 g. appropriate I to 0.5 ml. distilled. C5H10NH, shaking the mixture 15 min. to a clear solution, keeping it overnight at room temperature, triturating with hot petr. ether, and crystallizing the solids from dilute alc. gave the following III (R, % yield, m.p. given): Ph, 94, 193°; o-MeC6H4, 90, 127°; p-MeC6H4, 82, 141°; β-C10H7, 77, 130°. A similar rearrangement was observed from the action of aromatic thiols on I to also give 1 H-1,2,4-triazoles, RN.CPh: N.C(COSR'):N (IV). Thus, heating 1 g. I and 1 g. R'SH at 110 1.5 hrs., cooling, triturating with petr. ether, and crystallizing the residue from EtOH gave the following IV (R, R', % yield, m.p. given): Ph, Ph, 41, 146°; Ph, p-MeC6H4, 62, 195°; o-MeC6H4, p-MeC6H4,- 55, 181; p-MeC6H4, p-MeC6H4, 41, 177°; β-C10H7, p-MeC6H4, 46, 183°.
IT 111384-11-3P, Piperidine, 1-(1,5-diphenyl-1H-1,2,4-triazol-3-ylcarbonyl)- 115101-88-7P, Piperidine, 1-[5-phenyl-1-p-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 115163-48-9P, Piperidine, 1-[5-phenyl-1-o-tolyl-1H-1,2,4-triazol-3-ylcarbonyl]- 122680-69-5P, Piperidine, 1-[1-(2-naphthyl)-5-phenyl-1H-1,2,4-triazol-3-ylcarbonyl]-
RL: PREP (Preparation)
(preparation of)
RN 111384-11-3 CAPLUS
CN Methanone, (1,5-diphenyl-1H-1,2,4-triazol-3-yl)-1-piperidinyl- (CA INDEX NAME)



RN 115101-88-7 CAPLUS
CN Methanone, [1-(4-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 115163-48-9 CAPLUS
CN Methanone, [1-(2-methylphenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



RN 122680-09-5 CAPLUS
CN Methanone, [1-(2-naphthalenyl)-5-phenyl-1H-1,2,4-triazol-3-yl]-1-piperidinyl- (CA INDEX NAME)



=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 11:31:24 ON 30 MAR 2009